The local literature lacks comprehensive information regarding the actual incidence of intrauterine growth restriction (IUGR) and oligohydramnios and currently available therapeutic options. Therefore, the current study was planned with the objective to evaluate the impact of enoxaparin therapy compared with standard management on neonatal outcomes in pregnancies complicated by intrauterine growth restriction (IUGR) with oligohydramnios.
Women aged 18-40 years
Singleton pregnancy
Gestational age ≥28 weeks (confirmed by first-trimester scan or reliable last menstrual period)
Diagnosed with both IUGR and oligohydramnios
Multiple gestation
Major fetal congenital anomalies
Maternal medical disorders affecting pregnancy outcome (e.g., uncontrolled diabetes, chronic hypertension, renal disease)
Known coagulation disorders or contraindications to enoxaparin
Parallel
Enoxaparin
DrugPatients will receive standard management plus enoxaparin 40 mg subcutaneously once daily until delivery
Standard Management
Other interventionPatients will continue with standard management alone.
Live birth
The frequency of live birth will be noted. Delivery of a baby with signs of life at birth, irrespective of gestational age will be considered as live birth.
Low Birth weight
Frequency of low birth weight will be noted. Neonatal birth weight \<2.5 kg will be documented as low birth weight.
Neonatal Intensive Care Unit Admission
The frequency of admission to the neonatal intensive care unit will be noted.
Perinatal Mortality
Perinatal mortality will be labeled "yes" if there is a stillbirth or neonatal death within the first 7 days of life.
Click on the lead sponsor to view all of their trials.
Muhammad Aamir Latif
Lead sponsor
RESnTEC, Institute of Research
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
